title: Acquired activated protein C resistance in sarcoma patients.
abstract: Acquired activated protein C resistance (aAPCR) is seen more frequently in solid and hematological cancer patients. We aimed to investigate the presence of aAPCR and the frequency of clinically detectable thrombosis in sarcoma patients. Normalized activated protein C sensitivity ratio (nAPCSR), factor V Leiden (FVL) mutation, factor V (FV) levels and factor VIII (FVIII) levels were prospectively measured in 52 patients and in 52 healthy controls. Clinically detectable thrombosis was present in one patient (1.92%). Compared with healthy controls (106%), the sarcoma patients had significantly lower values of the nAPCSR at pre (87.25%) and post (94.35%) treatment period (P < 0.0001). aAPCR was found as 4.2, 13 and 0%, respectively. The post-treatment FV levels (178.1 U/dl) were significantly (P < 0.001) higher than the pretreatment levels (147.5 U/dl). Inverse correlation was found between post-treatment FV levels and nAPCSR values (r = -0.38, P < 0.02). We found out a slightly increased frequency of venous thromboembolism in sarcoma patients. As an original finding which has not been reported previously in the literature, we also found out a decrease in the nAPCSR, persisting even after treatment. Thirdly, we found out that the significantly higher rate of aAPCR at the time of diagnosis totally disappeared after treatment.
authors.affiliation: Department of Hematology, Ege University Medical School, Izmir, Turkey.
authors.forename: Nur
authors.initials: N
authors.lastname: Soyer
authors.forename: Burcin
authors.initials: B
authors.lastname: Kececi
authors.forename: Zuhal
authors.initials: Z
authors.lastname: Eroglu
authors.forename: Serra
authors.initials: S
authors.lastname: Kamer
authors.forename: Cagri
authors.initials: C
authors.lastname: Ozcelik
authors.forename: Seckin
authors.initials: S
authors.lastname: Cagirgan
authors.forename: Murat
authors.initials: M
authors.lastname: Tombuloglu
authors.forename: Dundar
authors.initials: D
authors.lastname: Sabah
authors.forename: Ayhan
authors.initials: A
authors.lastname: Donmez
mesh_terms: D020016:Activated Protein C Resistance / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D001859:Bone Neoplasms / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D016022:Case-Control Studies; D002648:Child; D005165:Factor V / Q000032:analysis / Q000235:genetics; D005169:Factor VIII / Q000032:analysis; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009154:Mutation; D011446:Prospective Studies; D012509:Sarcoma / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy; D013997:Time Factors; D054556:Venous Thromboembolism / Q000097:blood / Q000150:complications* / Q000188:drug therapy / Q000532:radiotherapy
chemical_list: D000970:Antineoplastic Agents; C095381:factor V Leiden; D005165:Factor V; D005169:Factor VIII